Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
The recurrence of hepatocellular carcinoma (HCC), two years after curative treatment is high,
about 40% - 50%. Recently, it has been shown that intra-arterial radioactive lipiodol
(Lipiocis®) could reduce the recurrence of cancer and increase the survival after resection
of HCC developed on cirrhosis B. The aim of the present trial is to investigate the effect of
Lipiocis® in preventing recurrence after curative treatment of HCC in patients with viral or
alcoholic hepatitis related cirrhosis by surgical or percutaneous ablation.
Phase:
Phase 3
Details
Lead Sponsor:
ANRS, Emerging Infectious Diseases French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)